Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Oct;4(4):439–444. doi: 10.1128/aac.4.4.439

Antiviral Activity of Cytarabine in Herpesvirus–Infected Rats

Harold E Renis 1
PMCID: PMC444574  PMID: 4364763

Abstract

Intranasal inoculation of herpesvirus (approximately 1.8 mean lethal doses [LD50] in 0.1 ml) into 105- to 115-g rats produces paralytic disease in 4 to 5 days and 80 to 100% mortality in 8 to 12 days. Cytarabine (ara-C) (40 to 320 mg/kg), administered subcutaneously to inoculated rats, delays the onset of paralysis and protects the animals from death. Drug treatments were given twice daily for 5 days. Beneficial drug effects were observed even when initiation of therapy was delayed for 3 days after virus inoculation. A dose-response relationship existed when therapy was initiated at 4 h after virus inoculation. However, when therapy was delayed for 3 days, it appeared that the highest drug level (320 mg/kg twice daily) was somewhat less effective than the lower doses (160 and 80 mg/kg twice daily). Virus could be detected in homogenates of brain beginning 3 days after inoculation, and the titer increased through 7 days. Ara-C treatment, initiated 4 h after inoculation, caused a delay in the appearance of virus, and a reduction in the titer in the brain homogenates. No virus was detected in blood serum, or in homogenates prepared from lung, kidney, thymus, or spleen of infected rats. The virus titration studies are in agreement with the illness and mortality produced by herpesvirus infection.

Full text

PDF
439

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Porat T., Brown M., Kaplan A. S. Effect of 1-beta-D-arabinofuranosylcytosine on DNA synthesis. II. In rabbit kidney cells infected with herpes viruses. Mol Pharmacol. 1968 Mar;4(2):139–146. [PubMed] [Google Scholar]
  2. CHU M. Y., FISCHER G. A. COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE. Biochem Pharmacol. 1965 Mar;14:333–341. doi: 10.1016/0006-2952(65)90198-x. [DOI] [PubMed] [Google Scholar]
  3. Camiener G. W., Smith C. G. Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol. 1965 Oct;14(10):1405–1416. doi: 10.1016/0006-2952(65)90175-9. [DOI] [PubMed] [Google Scholar]
  4. Chaube S., Kreis W., Uchida K., Murphy M. L. The teratogenic effect of 1-beta-D-arabinofuranosylcytosine in the rat. Protection by deoxycytidine. Biochem Pharmacol. 1968 Jul;17(7):1213–1216. doi: 10.1016/0006-2952(68)90058-0. [DOI] [PubMed] [Google Scholar]
  5. Chow A. W., Foerster J., Hryniuk W. Cytosine arabinoside therapy for herpesvirus infections. Antimicrob Agents Chemother (Bethesda) 1970;10:214–217. [PubMed] [Google Scholar]
  6. Cohen S. S. Introduction to the biochemistry of D-arabinosyl nucleosides. Prog Nucleic Acid Res Mol Biol. 1966;5:1–88. doi: 10.1016/s0079-6603(08)60231-7. [DOI] [PubMed] [Google Scholar]
  7. Durham J. P., Ives D. H. Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation. Mol Pharmacol. 1969 Jul;5(4):358–375. [PubMed] [Google Scholar]
  8. EVANS J. S., MUSSER E. A., MENGEL G. D., FORSBLAD K. R., HUNTER J. H. Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride. Proc Soc Exp Biol Med. 1961 Feb;106:350–353. [PubMed] [Google Scholar]
  9. Fischer D. S., Cassidy E. P., Welch A. D. Immunosuppression by pyrimidine nucleoside analogs. Biochem Pharmacol. 1966 Aug;15(8):1013–1022. doi: 10.1016/0006-2952(66)90265-6. [DOI] [PubMed] [Google Scholar]
  10. Furth J. J., Cohen S. S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res. 1968 Oct;28(10):2061–2067. [PubMed] [Google Scholar]
  11. Glenn E. M. Inhibition of adjuvant-induced polyarthritis with cytarabine. Proc Soc Exp Biol Med. 1968 Dec;129(3):860–865. doi: 10.3181/00379727-129-33443. [DOI] [PubMed] [Google Scholar]
  12. Gordon R. O., Wade M. E., Mitchell M. S. The production of tolerance to human erythrocytes in the rat with cytosine arabinoside or cyclophosphamide. J Immunol. 1969 Aug;103(2):233–243. [PubMed] [Google Scholar]
  13. Gray G. D., Crim J. A., Mickelson M. M. The immunosuppressive activity of ara-cytidine. II. Effects on the graft-versus-host reaction. Transplantation. 1968 Oct;6(7):818–825. doi: 10.1097/00007890-196810000-00002. [DOI] [PubMed] [Google Scholar]
  14. Gray G. D., Mickelson M. M., Crim J. A. The immunosuppressive activity of ara-cytidine. I. Effects on antibody-forming cells and humoral antibody. Transplantation. 1968 Oct;6(7):805–817. doi: 10.1097/00007890-196810000-00001. [DOI] [PubMed] [Google Scholar]
  15. Gray G. D., Mickelson M. M. The immunosuppressive effects of adamantoyl cytarabine. II. Effects on skin allograft rejection by rats and mice. Transplantation. 1970 Feb;9(2):176–178. [PubMed] [Google Scholar]
  16. Greig M. E., Gibbons A. J. Effects of cytarabine and adamantoyl cytarabine on experimental allergic encephalomyelitis in rats. Arch Int Pharmacodyn Ther. 1969 Dec;182(2):364–369. [PubMed] [Google Scholar]
  17. Hall T. C., Wilfert C., Jaffe N., Traggis D., Lux S., Rompf P., Katz S. Treatment of varicella-zoster with cytosine arabinoside. Trans Assoc Am Physicians. 1969;82:201–210. [PubMed] [Google Scholar]
  18. Hryniuk W., Foerster J., Shojania M., Chow A. Cytarabine for herpesvirus infections. JAMA. 1972 Feb;219(6):715–718. [PubMed] [Google Scholar]
  19. Inagaki A., Nakamura T., Wakisaka G. Studies on the mechanism of action of 1-beta-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. Cancer Res. 1969 Dec;29(12):2169–2176. [PubMed] [Google Scholar]
  20. Juel-Jensen B. E. Severe generalized primary herpes treated with cytarabine. Br Med J. 1970 Apr 18;2(5702):154–155. doi: 10.1136/bmj.2.5702.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. KAUFMAN H. E., MALONEY E. D. IDU and cytosine arabinoside in experimental herpetic keratitis. Arch Ophthalmol. 1963 May;69:626–629. doi: 10.1001/archopht.1963.00960040632017. [DOI] [PubMed] [Google Scholar]
  22. Kaplan A. S., Brown M., Ben-Porat T. [Effect of 1-beta-D-arabinofuranosylcytosine on DNA synthesis. 1. In normal rabbit kidney cell cultures]. Mol Pharmacol. 1968 Mar;4(2):131–138. [PubMed] [Google Scholar]
  23. Kline I., Tyrer D. D., Venditti J. M., Waravdekar V. S., Gang M. Effectiveness of cytosine arabinoside therapy on leukemia (L-1210) of the central nervous system in mice arising during methotrexate treatment. Gan. 1968 Dec;59(6):527–535. [PubMed] [Google Scholar]
  24. Kline I., Venditti J. M., Tyrer D. D., Mantel N., Goldin A. Chemotherapy of leukemia L1210 in mice with 1-beta-D-arabinofuranosylcytosine hydrochloride. II. Effectiveness against intracerebrally and subcutaneously inoculated leukemic cells. Cancer Res. 1966 Sep;26(9):1930–1937. [PubMed] [Google Scholar]
  25. Lenaz L., Philips F. S. Effects of arabinosylcytosine nucleosides on DNA synthesis in rats. Cancer Res. 1970 Jul;30(7):1961–1962. [PubMed] [Google Scholar]
  26. Leopold I. H. Clinical experience with nucleosides in herpes simplex eye infections in man and animals. Ann N Y Acad Sci. 1965 Jul 30;130(1):181–191. doi: 10.1111/j.1749-6632.1965.tb12551.x. [DOI] [PubMed] [Google Scholar]
  27. Mitchell M. S., Kaplan S. R., Calabresi P. Alteration of antibody synthesis in the rat by cytosine arabinoside. Cancer Res. 1969 Apr;29(4):896–904. [PubMed] [Google Scholar]
  28. Prince H. N., Grunberg E., Buck M., Cleeland R. A comparative study of the antitumor and antiviral activity of 1-beta-D-arabinofuranosyl-5-fluorocytosine (FCA) and 1-beta-D-arabinofuranosylcytosine (CA). Proc Soc Exp Biol Med. 1969 Apr;130(4):1080–1086. doi: 10.3181/00379727-130-33724. [DOI] [PubMed] [Google Scholar]
  29. ROTHERHAM J., SCHNEIDER W. C. Deoxyribosyl compounds in animal tissues. J Biol Chem. 1958 Jun;232(2):853–858. [PubMed] [Google Scholar]
  30. Renis H. E. Comparison of cytotoxicity and antiviral activity of 1-beta-D-arabino-furanosyl-5-iodocytosine with related compounds. Cancer Res. 1970 Jan;30(1):189–194. [PubMed] [Google Scholar]
  31. Renis H. E., Hollowell C. A., Underwood G. E. Nucleic acids. 3. Antiviral activity of nucleotides and dinucleoside phosphates containing ara-cytidine. J Med Chem. 1967 Sep;10(5):777–782. doi: 10.1021/jm00317a005. [DOI] [PubMed] [Google Scholar]
  32. SCHNEIDER W. C. Deoxyribosides in animal tissues. J Biol Chem. 1955 Sep;216(1):287–301. [PubMed] [Google Scholar]
  33. Sidwell R. W., Dixon G. J., Sellers S. M., Schabel F. M., Jr In vivo antiviral properties of biologically active compounds. II. Studies with influenza and vaccinia viruses. Appl Microbiol. 1968 Feb;16(2):370–392. doi: 10.1128/am.16.2.370-392.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. UNDERWOOD G. E. Activity of 1-beta-D-arabinofuranosylcytosine hydrochloride against herpes simplex keratitis. Proc Soc Exp Biol Med. 1962 Dec;111:660–664. doi: 10.3181/00379727-111-27884. [DOI] [PubMed] [Google Scholar]
  35. Wodinsky I., Kensler C. J. Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors. Cancer Chemother Rep. 1965 Aug;47:65–68. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES